The 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) will be hold in Jinan, Shandong Province from September 10 to 14. Centered on the theme "Standardized Diagnosis and Treatment, Innovation-Driven", the conference showcases China's most cutting-edge and influential research achievements in clinical oncology, focusing on clinical needs and sharing practical experience. Multiple research findings from Scitech Pharma's ST-1898 and ST-1703 projects were selected for presentation in the Innovative Drug Clinical Research Data Session and the Malignant Melanoma Session, respectively.

Since receiving approval from the National Medical Products Administration (NMPA) in July 2020 to initiate clinical trials, ST-1898 tablets have advanced into Phase II clinical trials for three indications: renal cell carcinoma, thyroid cancer, and melanoma. ST-1898 has also demonstrated potential across multiple tumor types during Phase I trials. Among these, the renal cell carcinoma and melanoma indications have completed Phase II trials and are poised to enter pivotal Phase III clinical studies. At this conference, the latest clinical research findings and future research priorities for ST-1898 tablets in melanoma and renal cell carcinoma will be presented through oral reports.

ST-1703 tablets, as Scitech Pharma's second drug candidate to enter clinical development, are intended for the treatment of HER2-positive advanced solid tumors (including patients with brain metastases). The conference will present the results of the Phase I/IIa clinical trial for ST-1703 tablets and outline future research directions.

Scitech Pharma